Publications

Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. by Sader HS, Carvalhaes CG, Mendes RE and Castanheira M. published in Int. J. Infect. Dis. 2022; 116: 306-312

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. by Pfaller MA, Huband MD, Shortridge D and Flamm RK. published in J. Glob. Antimicrob. Resist. 2021; 27: 337-351

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. by Castanheira M, Doyle TB, Collingsworth TD, Sader HS and Mendes RE. published in J. Antimicrob. Chemother. 2021; 76 (12): 3125-3134

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. by Sader HS, Castanheira M, Duncan LR and Mendes RE. published in Int. J. Infect. Dis. 2021; 113: 279-281

Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018-2020). by Sader HS, Mendes RE, Streit JM, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 2022; 102 (1): 115557

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis, and Candida glabrata, Lead author: CG Carvalhaes presented at 10th Trends in Medical Mycology (TIMM10), October 8-11, Virtual and Abdereen, Scotland, UK.
Poster # 338

Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. by Castanheira M, Doyle TB, Deshpande LM, Mendes RE and Sader HS. published in Int. J. Antimicrob. Agents. 2021; 58 (5): 106439

Evaluation of the In Vitro Activity of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from the United States: Results from 10 Years of the AWARE Surveillance Program (2011-2020), Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Infective Endocarditis from the United States and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program, Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL
Poster #36440

Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Meropenem-Vaborbactam In Vitro Activities against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers in 2020 presented, Lead author: HS Sader. Presented at American Thoracic Society (ATS) 2021, May 14-19, Virtual Conference
Poster #8470

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. by Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS and Castanheira M published in J. Antimicrob. Chemother. 2021; 76 (11): 2833-2838

Minocycline activity against unusual clinically significant Gram-negative pathogens. by Shortridge D, Arends SJR, Streit JM and Castanheira M. published in Antimicrob. Agents Chemother.
2021; 65 (11): e01264

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: Results from the SENTRY Antimicrobial Surveillance Program (2016-19). by Sader HS, Streit JM, Carvalhaes CG, Huband MD, Shortridge D, Mendes RE and Castanheira M. published in JAC – Antimicrob. Resist. 2021; dlab117

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. by Sader HS, Mendes RE, Doyle TB, Davis AP and Castanheira M. JAC Antimicrob. Resist. 2021; 3 (3): dlab136

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. by Sader HS, Duncan LR, Doyle TB and Castanheira M. published in JAC Antimicrob. Resist. 2021; 3 (3): dlab126

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against a Recent Collection of Fastidious Organisms Recovered from Respiratory Tract Infections. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Five-Year Trends on the Susceptibility of Enterobacterales to Plazomicin and Other Aminoglycosides in Hospitals in the United States (2016-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary ESBL-Producing and CRE Isolates, Including Isolates Producing Metallo-β-Lactamases. Lead author: J Lindley presented at IDWeek 2021, September 29-October 3, Virtual Conference

Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftibuten-Avibactam against Clinical Isolates of Enterobacterales Producing Clinically Relevant Beta-Lactamases. Lead author: HS SAder presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized, Fluoroquinolone-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020. Lead author: LR Duncan presented at IDWeek 2021 September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Tebipenem In Vitro Activity against a Collection of Pathogens Responsible for Urinary Tract Infections in the US. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Meropenem-Vaborbactam and Comparator Agents against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobcter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Cefiderocol and Comparators against Gram-Negative Isolates from US Patients Hospitalized with Pneumonia. Lead author: D Shortridge presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Gram-Negative Bacteria Isolated from Bloodstream and Complicated Urinary Tract Infections in Europe, Asia, and Latin America (2019-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Epidemiology and Susceptibility Profiles of ST131-025b Escherichia coli Detected Among Cephalosporin- and/or Carbapenem-Resistant Isolates Collected in United States Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Optimization of a 96-Well Plate Format Assay to Evaluate Concentration-Dependent Activity of a Monoclonal Antibody against the O Antigen 025b from ST131-H30 Escherichia coli. Lead author: J Lindley presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused by Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-Ocrtober 3, Virtual Conference

Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and In Vitro Activity of Tebipenem, Including against Strain Lineage and Resistant Subsets (2018-2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Minocycline activity against Acinetobacter baumannii-calcoaceticus species complex, Burkholderia cepacia complex, and Stenotrophomonas maltophilia from US hospitals. Lead author: D Shortridge, presented at IDWeek 2021, September 29-October 3, Virtual Conferece

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19). by Shortridge D, Carvalhaes C, Deshpande L and Castanheira M. published in J Antimicrob Chemother. 2021; 76 (10): 2600-2605

Antimicrobial Susceptibility of Gram-negative Organisms from Southeast Asia. Lead author: H Sader presented at 13th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2021), September 9-10, 2021, Virtual Conference
Poster #0323

Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019. by Huang DB, Sader HS, Rhomberg PR, Gaukel E and Borroto-Esoda K. published in Diagn. Microbiol. Infect. Dis. 2021; 101 (3): 115471

Antifungal drugs work together to treat germs causing fungal infections. by Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA and Castanheira M. published in Future Microbiol. 2021; 16: 765-768